Our Publicationskari.sharp@gmail.com2026-01-29T16:40:01-08:00

PUBLICATIONS

Apply filters from dropdown menus:

How Molecular Testing is Changing Melanoma Treatments with Dr. Alex Meves SkylineDx
Meves et al., Empowered Patient.

August 2025

Read More
Validation of a Clinicopathologic and Gene Expression Model for Predicting Sentinel Node Metastasis in Melanoma: A Multicenter Danish Cohort Study
Weitemeyer et al., Journal of Surgical Oncology.

July 2025

Read More
Identification of patients at high risk for relapse by Merlin assay (CP-GEP) in an independent cohort of melanoma patients (pts) that did not undergo sentinel lymph node biopsy: An H&N subgroup analysis.
Amaral et al., 2025. ASCO Conference.

May 2025

Read More
Risk stratification using the Merlin Assay (CP-GEP) in an independent cohort of 930 patients with clinical stage I/II melanoma who did not undergo sentinel lymph node biopsy
Amaral et al., European Journal of Cancer.

May 2025

Read More
Prospective multicenter evaluation (MERLIN_001 trial) of a clinicopathologic and gene expression profile test to predict sentinel node status in T1-T3 cN0 melanoma
Hieken et al., SSO Conference.

April 2025

Read More
Prospective multicenter evaluation (MERLIN_001 trial, NCT04759781) of a clinicopathologic and gene expression profile test to predict sentinel node status in T1-T3 cN0 melanoma
Hieken et al., SSO Conference.

April 2025

Read More
Using a clinicopathologic and gene expression model to predict sentinel lymph node metastasis in primary cutaneous melanoma could reduce the rate of sentinel lymph node biopsies with >70%: a multicentre Danish cohort study.
Weitemeyer et al., 2023. EADO Conference.

April 2025

Read More
Identification of patients at high risk for relapse using the Merlin Assay (CP-GEP) in an independent cohort of 930 patients (pts) with stage I/II melanoma who did not undergo sentinel lymph node biopsy
Amaral et al., 2025. World Congress of Melanoma.

March 2025

Read More
Clinicopathologic and gene expression profile (CP-GEP) is a biomarker for outcome in patients with melanoma eligible for sentinel lymph node biopsy (SLNB)
Zijlker et al., 2025. World Congress of Melanoma.

March 2025

Read More
Using CP-GEP model (Merlin Assay) to stratify melanoma patients on long-term survival in a multi-continent cohort study
Utikal et al., 2025. World Congress of Melanoma.

March 2025

Read More
Prospective multicenter evaluation of a clinicopathologic and gene expression profile test to predict sentinel node status in T1-T3 cN0 melanoma: updated MERLIN_001 trial
Heiken et al., 2025. World Congress of Melanoma.

March 2025

Read More
Assessing risk of nodal metastasis and relapse-free survival by CP-GEP (Merlin™ Test) in a single-center retrospective case series of stage pT1a-4b cN0M0 melanoma patients
Kessels et al., 2025. World Congress of Melanoma.

March 2025

Read More
Using a clinicopathologic and gene expression profile (CP-GEP) model to predict prognosis in stage I-II melanoma
Weitemeyer et al., 2024. Australasian Melanoma Conference

October 2024

Read More
Prospective multicenter evaluation (MERLIN_001 trial) of a clinicopathologic and gene expression profile test to predict sentinel node status in T1-T3 cN0 melanoma
Sondak et al., SMR Conference.

October 2024

Read More
CP-GEP Identifies T1a Melanoma Patients At Risk of Sentinel Lymph Node Metastasis
W. Yu et al. 2024. SMR Conference.

October 2024

Read More
Impact of CP-GEP to improve selection of patients with melanoma who may forgo sentinel lymph node biopsy based on real world data
Stassen et. al., EADV 2024

September 2024

Read More
Identification of patients at high risk for relapse by Merlin Assay (CP-GEP) in an independent cohort of melanoma patients (pts) that did not undergo sentinel lymph node biopsy: a H&N subgroup analysis.
Amaral et al., 2024. ASCO conference.

May 2024

Read More
Identification of patients at high risk for relapse using the Merlin Assay (CP-GEP) in an independent cohort of 432 patients with stage I/II melanoma who did not undergo sentinel lymph node biopsy
Amaral et al., American Society of Clinical Oncology

May 2024

Read More
Predictive Performance of the Clinicopathologic Gene Expression Profile (CP-GEP) in Identifying Cutaneous Melanoma Patients for Whom Sentinel Lymph Node Biopsy is Unnecessary: A Systematic Review and Meta-Analysis.
T. Wong et. al., 2024. AMC Congress

May 2024

Read More
Enhanced Risk Stratification for Sentinel Lymph Node Biopsy in Head and Neck Melanoma Using the Merlin Assay (CP-GEP)
Pazhava et al., Annals of Surgical Oncology

April 2024

Read More
Using a clinicopathologic and gene expression model to predict prognosis in stage I-II primary cutaneous melanoma: a multicenter Danish cohort study.
Weitemeyer et al., 2024. EADO conference.

April 2024

Read More
Identification of patients at high risk for relapse by Merlin Assay (CP-GEP) in an independent cohort of melanoma patients (pts) that did not undergo sentinel lymph node biopsy: a H&N subgroup analysis.
Amaral et al., European Association of Dermato-Oncology

April 2024

Read More
Head & neck primary cutaneous melanoma patients stratified by CP-GEP (Merlin Assay): risk of nodal metastasis and long-term survival outcome.
Pittelkow et al., 2024. SSO conference.

March 2024

Read More
Primary cutaneous melanoma patients stratified by the Merlin assay (CP-GEP): risk of nodal metastasis and long-term survival outcome in a U.S. cohort.
Hill et al., 2024. AAD conference

March 2024

Read More
Long-term follow-up of melanoma patient risk stratified by a clinicopathologic and gene expression profile (CP-GEP) model: a -center United States cohort study.
W. Yu et al. 2024. SMR Conference.

November 2023

Read More
Clinical evaluation of the clinicopathologic and gene expression profile (CP-GEP) in patients with melanoma eligible for sentinel lymph node biopsy: a multicenter prospective Dutch study
Stassen et al., European Journal of Surgical Oncology

August 2023

Read More
Using a clinicopathologic and gene expression model to predict sentinel lymph node metastasis in primary cutaneous melanoma could reduce the rate of sentinel lymph node biopsies with >70%: a multicentre Danish cohort study
Weitemeyer et al., EADO Conference

August 2023

Read More
Using a clinicopathologic and gene expression model to predict sentinel lymph node metastasis in primary cutaneous melanoma could reduce the rate of sentinel lymph node biopsies with >70%: a multicentre Danish cohort study.
Marie Weitemeyer et al., 2023. EADO Conference.

April 2023

Read More
MERLIN_001: A prospective registry study of a primary melanoma gene-signature to predict sentinel node (SN) status and determine its prognostic value for more accurate staging of SN-negative melanoma patients.
Hieken et al., AACR 2023

April 2023

Read More
Identification of stage I/II melanoma patients at high risk for recurrence using a model combining clinicopathologic factors with gene expression profiling (CP-GEP).
Amaral et al. 2022. European Journal of Cancer.

March 2023

Read More
Breslow thickness 2.0: Why gene expression profiling is a step toward better patient selection for sentinel lymph node biopsies
Sadurní et al., Modern Pathology.

November 2022

Read More
Cost evaluation of the Merlin assay for predicting melanoma sentinel lymph node biopsy metastasis.
Thao et al. 2022. International Journal of Dermatology.

November 2022

Read More
Using the Merlin Assay for reducing sentinel lymph node biopsy complications in melanoma: a retrospective cohort study.
Hieken et al. 2022. International Journal of Dermatology.

July 2022

Read More
Prognostic significance of the CP-GEP assay combining clinicopathological factors and gene expression profiling in AJCC v8 stage I/II cutaneous melanoma patients.
Amaral et al. 2022. ASCO Conference.

June 2022

Read More
Use of Merlin Assay to identify patients with a low-risk for SN metastasis in a prospective multicenter Dutch study of a primary melanoma gene-signature (CP-GEP model) to predict sentinel node status during COVID-19.
Stassen et al. 2022. ASCO Conference.

June 2022

Read More
MERLIN_001: A prospective registry study of a primary melanoma gene signature to predict sentinel node (SN) status and determine its prognostic value for more accurate staging of SN-negative melanoma patients.
Hieken et al. 2022. ASCO Conference.

June 2022

Read More
Using a clinicopathologic and gene expression (CP-GEP) model to identify stage I-II melanoma patients at risk of disease relapse.
Mulder et al. 2022. Cancers.

June 2022

Read More
Use of CP-GEP to identify primary cutaneous melanoma patients with low risk for SN metastasis in a prospective multicenter Dutch study during COVID-19.
Stassen et al. 2022. EADO Conference.

April 2022

Read More
Using the Merlin assay for reducing sentinel lymph node biopsy complications in melanoma: a retrospective cohort study
Hieken et al., NCCN 2022

April 2022

Read More
Cutaneous melanoma patients with minimal SN tumor burden: CP-GEP (Merlin Assay) may guide decision-making beyond nodal assessment.
Tjien-Fooh et al. 2022. AAD Conference.

March 2022

Read More
Validation of a clinicopathological and gene expression profile model to identify patients with cutaneous melanoma where sentinel lymph node biopsy is unnecessary.
Johansson et al. 2021. European Journal of Surgical Oncology.

February 2022

Read More
Validation of CP-GEP (Merlin Assay) for predicting sentinel lymph node metastasis in primary cutaneous melanoma patients: a U.S. cohort study.
Yousaf & Tjien-Fooh et al., 2021. International Journal of Dermatology.

July 2021

Read More
Independent validation study of CP-GEP model (Merlin Assay) to identify patients who can safely forgo sentinel lymph node biopsy.
Johansson et al. 2021. EADO Conference.

April 2021

Read More
Using the clinicopathologic and gene expression (CP-GEP) model to predict sentinel node status in patients with primary melanoma: a prospective cohort study during the COVID-19 pandemic.
Mulder et al. 2021. EADO Conference.

April 2021

Read More
Using a clinicopathologic and gene expression (CP-GEP) model in a European cohort to identify stage II melanoma patients at high risk for disease relapse.
Mulder et al. 2021. EADO Conference.

April 2021

Read More
Validation of a clinicopathological and gene expression profile model for sentinel lymph node metastasis in primary cutaneous melanoma
Mulder et al., British Journal of Dermatology.

January 2021

Read More
Primary cutaneous melanoma risk stratification using a clinicopathologic and gene expression model: a pilot study.
Arias-Mejias et al. 2020. International Journal of Dermatology.

November 2020

Read More
Deselecting melanoma patients for sentinel lymph node biopsy during COVID-19: clinical utility of tumor molecular profiling.
Meves & Eggermont 2020. Mayo Clin Proc Inn Qual Out.

October 2020

Read More
The use of a clinicopathologic and gene expression model (Merlin Assay) to risk stratify cutaneous melanoma patients in clinical practice: A pilot study.
Bridges et al. 2020. ASDP Conference.

October 2020

Read More
Validation of a Model Combining Clinicopathologic Risk Factors and a Gene Expression Profile to Identify Primary Melanoma Patients Who Can Safely Forgo Sentinel Lymph Node Biopsy.
Yousaf et al. 2020. ESMO

September 2020

Read More
Validation of a clinicopathological and gene expression profile model for sentinel lymph node metastasis in primary cutaneous melanoma.
Mulder et al. 2020. British Journal of Dermatology.

August 2020

Read More
Identification of stage I/IIA melanoma patients at high risk for disease relapse using a clinicopathologic and gene expression model
Eggermont et al. 2020. European Journal of Cancer.

August 2020

Read More
Identification of stage IIA melanoma patients at high risk for disease relapse using a clinicopathologic and gene expression model.
Wever et al. 2020. ASCO Conference.

June 2020

Read More
Using a clinicopathologic and gene expression model to identify melanoma patients at high risk for disease relapse.
Eggermont et al. 2020. ASCO Conference.

June 2020

Read More
Model combining tumor molecular and clinicopathologic risk factors predicts sentinel lymph node metastasis in primary cutaneous melanoma.
Bellomo et al. 2020. JCO Precision Oncology.

April 2020

Read More
A combined clinicopathologic and gene expression model (CP-GEP) identifies primary cutaneous melanoma patients who can safely forgo sentinel lymph node biopsy.
Meves et al. 2020. AAD Conference.

March 2020

Read More
Validation of a ClinicoPathological and Gene Expression Profile (CP-GEP) model for sentinel lymph node metastasis in primary cutaneous melanoma.
Mulder et al. 2019. ESMO Conference.

May 2019

Read More
Stromal gene expression predicts sentinel lymph node metastasis of primary cutaneous melanoma Sominidi-Damodaran et al. 2019. EADO conference.
Sominidi-Damodaran et al. 2019. EADO conference.

April 2019

Read More
A molecular model to identify patients who can safely forgo sentinel lymph node biopsy in primary cutaneous melanoma.
Bellomo et al. 2019. CIM Conference.

April 2019

Read More